Rohto Medical business
to launch wearable medical device for managing overactive bladder symptoms in the Chinese market –marking the first step in its global expansion of its medical business.
March 16, 2026
ROHTO Pharmaceutical Co., Ltd., Ltd. (Headquarters: Osaka, President and Representative Director: Hidetoshi Segi) is pleased to announce its entry into the Chinese market through Mentholatum (Asia-Pacific) Limited [Hong Kong], with a non-invasive wearable medical device that manages symptoms of overactive bladder in conjunction with an AI app. This acquisition of sales rights for the Asian region is the result of a partnership with Australis Scientific Pty Ltd., a health tech venture spun off from the Harvard Innovation Lab, in which Rohto invested in 2023. This product utilizes neuromodulation technology to support the normalization of bladder function and is a medical device that is attached to the body for use in everyday environments such as at home. Sales in the Chinese market are scheduled to begin in June 2026, aiming to provide a new healthcare solution that makes it easier to manage chronic diseases in daily life.
Background
Our company operates with the purpose of leading all individuals and society around us to "well-being" by delivering "health" to people around the world through our products and services.
Urinary problems such as overactive bladder tend to increase with age, yet they are often difficult to discuss with others in daily life, leading to delays in seeking medical attention and starting treatment. Persistent symptoms can impact quality of life, causing people to avoid going out or disrupting their sleep. Even with invasive treatment and care options available, the burden of hospital visits and the difficulty of maintaining them can hinder adequate care. Therefore, in addition to hospital treatment, there is a need for sustainable and manageable approaches to care within daily life.
This product was acquired in December 2025 as an NMPA Class II medical device in China, and a basic agreement was signed in February 2026 with Australis Scientific Pty Ltd. and the manufacturer, Beijing InnoStim Technology Co. Ltd., in preparation for launch in the Chinese market, where there is a growing need for home healthcare solutions due to the increasing need to address urinary problems caused by aging, as well as a high level of interest in digital health and wearable medical devices.
Product features
A wearable therapeutic device that modulates nerve activity related to the bladder.
By using neuromodulation technology to support the regulation of nerve signals between the bladder and the brain, we help normalize bladder function.
It is a non-invasive treatment that places minimal burden on the body and can be used at home.
This smart patch device, worn on the ankle, supports the improvement of overactive bladder (OAB) symptoms with minimal burden on the body. It represents a new type of treatment approach that does not involve medication or surgery.
In conjunction with digital technology, we support continuous treatment management.
By linking with a smartphone app, you can manage device settings and check usage status. By collecting patient-reported outcome data (PRO), we can continuously monitor the progress of treatment and support long-term treatment management.
Supporting long-term treatment while reducing the burden of hospital visits.
Users can perform treatment at home for approximately 30 minutes, reducing the burden of hospital visits.
Product overview
| Common name |
Wearable smart patch for treating overactive bladder (OAB)
(The product name is currently undergoing trademark registration.) |
| classification |
medical devices |
| Contents and Price |
Treatment Complete Set 3,739 yuan (equivalent to approximately 84,600 yen *)
Pulse Generator (main unit) and Electrode patches (12 smart patches included)
(*Calculated using 1 USD = 7 RMB and 1 USD = 158.40 JPY) |
| Product image |
Image left: Pulse generator unit; Right: Patch (for right foot)
|
| Effects and Benefits |
This treatment aims to alleviate symptoms associated with overactive bladder (OAB), such as urinary urgency, frequent urination, nocturia, and urinary incontinence, and to improve quality of life (QOL). |
| How to use |
The smart patch is attached to the inside of the ankle, and the main unit is then attached to use it.
This smart patch-type wearable medical device uses neuromodulation technology to gently adjust nerve function and support the improvement of overactive bladder (OAB) symptoms. Treatment can be easily performed at home, once a day for approximately 30 minutes, several times a week. |
| Sales area |
China (mainland and Hong Kong), Macau |
| Sales channels |
E-commerce and medical channels such as medical institutions, clinics, and nursing care facilities. |
| manufacturer |
Beijing InnoStim Technology Co. Ltd. |
| Distributor |
The Mentholatum Company, Inc. Asia Pacific (Hong Kong) |
Future outlook
This product represents a new therapeutic approach combining wearable medical devices and digital technology, and we plan to continue research into its potential applications in various disease areas.
Going forward, we will continue to provide new treatment solutions for chronic diseases through the development and global expansion of innovative medical technologies, while also promoting the global expansion of Medical business within the group. We are committed to developing and disseminating solutions that improve the quality of life (QOL) of people in aging societies around the world.